Avanos Medical, Inc. $AVNS Shares Purchased by Tudor Investment Corp ET AL

Key Points

• Tudor Investment Corp ET AL increased its stake in Avanos by 509.6% in Q3, purchasing 60,099 shares to hold 71,893 shares (about 0.15% of the company) worth roughly $831,000.
• Avanos beat Q4 expectations with $0.29 EPS vs. $0.24 expected and $180.9M revenue vs. $174.7M, and issued FY2026 guidance of 0.900–1.100 EPS.
• Institutional ownership is high at 95.17%, but analyst sentiment is mixed-to-negative with a MarketBeat consensus rating of "Reduce" despite some recent upgrades and downgrades.

Tudor Investment Corp ET AL increased its stake in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 509.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 71,893 shares of the company's stock after purchasing an additional 60,099 shares during the period. Tudor Investment Corp ET AL owned 0.15% of Avanos Medical worth $831,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of AVNS. Versant Capital Management Inc raised its position in shares of Avanos Medical by 49.7% in the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company's stock valued at $31,000 after buying an additional 894 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company's stock valued at $31,000 after buying an additional 2,307 shares during the last quarter. Wexford Capital LP acquired a new stake in shares of Avanos Medical in the third quarter valued at about $70,000. Tower Research Capital LLC TRC raised its position in shares of Avanos Medical by 433.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company's stock valued at $77,000 after buying an additional 5,083 shares during the last quarter. Finally, Quantessence Capital LLC acquired a new stake in shares of Avanos Medical in the third quarter valued at about $116,000. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Avanos Medical Price Performance

Shares of AVNS opened at $24.63 on Wednesday. Avanos Medical, Inc. has a 1-year low of $9.30 and a 1-year high of $24.70. The stock has a market cap of $1.15 billion, a PE ratio of -15.59 and a beta of 1.05. The firm has a 50-day simple moving average of $14.27 and a two-hundred day simple moving average of $12.61. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.15 and a quick ratio of 1.26.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The business had revenue of $180.90 million during the quarter, compared to analysts' expectations of $174.70 million. During the same period last year, the business earned $0.43 earnings per share. The business's revenue for the quarter was up .7% on a year-over-year basis. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, analysts forecast that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AVNS shares. Weiss Ratings restated a "sell (d-)" rating on shares of Avanos Medical in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. Finally, Zacks Research upgraded shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Reduce".

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical, Inc. (NYSE:AVNS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.